Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Promega Partners with ATCC to Offer New Cell Systems for Biologics Drug Discovery

Published: Monday, June 27, 2011
Last Updated: Monday, June 27, 2011
Bookmark and Share
Partnership for the cell banking and bioproduction of cells to create a new line of bioluminescence-based drug discovery assays for biologics.

Promega Corporation and ATCC (historically known as the American Type Culture Collection) have formed a partnership for the cell banking and bioproduction of cells to create a new line of bioluminescence-based drug discovery assays for biologics.

In the partnership, ATCC will produce and authenticate cell banks and production lots of engineered and stock cell lines, which will be used as cellular reagents to create a new line of Promega cell assay systems for biologics. The initial cell assay system will facilitate biologics drug discovery.

Promega will launch an ADCC reporter bioassay in 2011 as the first product offering from this partnership. The ADCC (Antibody Dependent Cell-mediated Cytotoxicity) reporter bioassay will meet a particularly critical need for nearly all antibody-based biologics drug discovery programs worldwide.

These and other custom cell system assays will provide reduced variability to bioassays for biologics. The ADCC and other bioassay systems are currently in alpha and beta testing programs for qualification by leading manufacturers of biologics drugs.

ATCC is the recognized leader in biological materials management and processes for cell provisioning. "We are extremely pleased to work with Promega in bringing their assay innovations to drug discovery researchers", said Dr. Sherry Challberg, Sr. Director of Corporate Development for ATCC.

ATCC's President, Dr. Brian Pollok added, "We are excited to begin a venture of working with technology-based companies like Promega in the area of cellular assay product development."

Promega's Vice President of Life Sciences Products and Services, Thomas Livelli commented, "We believe this new offering will be extremely helpful to scientists and provide high value cell-based systems for discovery and development."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Promega to Break Ground for New Processing and Manufacturing Facility
Facility will allow for efficiency improvements for processing, packaging, staging and shipping products.
Monday, July 07, 2014
Promega Expansion into Brazil Brings New Convenience and Support for Scientists
Now scientists in life science research, drug discovery and clinical diagnostics have direct access to technical service, fast delivery and the ability to request a quote online in Brazil.
Thursday, April 07, 2011
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!